Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. (5th March 2019)

• Record Type: Journal Article
• Authors: Schuepbach, W.M. Michael; Tonder, Lisa; Schnitzler, Alfons; Krack, Paul; Rau, Joern; Hartmann, Andreas; Hälbig, Thomas D.; Pineau, Fanny; Falk, Andrea; Paschen, Laura; Paschen, Stephen; Volkmann, Jens; Dafsari, Haidar S.; Barbe, Michael T.; Fink, Gereon R.; Kühn, Andrea; Kupsch, Andreas; Schneider, Gerd-H.; Seigneuret, Eric; Fraix, Valerie; Kistner, Andrea; Chaynes, P. Patrick; Ory-Magne, Fabienne; Brefel-Courbon, Christine; Vesper, Jan; Wojtecki, Lars; Derrey, Stéphane; Maltête, David; Damier, Philippe; Derkinderen, Pascal; Sixel-Döring, Friederike; Trenkwalder, Claudia; Gharabaghi, Alireza; Wächter, Tobias; Weiss, Daniel; Pinsker, Marcus O.; Regis, Jean-Marie; Witjas, Tatiana; Thobois, Stephane; Mertens, Patrick; Knudsen, Karina; Schade-Brittinger, Carmen; Houeto, Jean-Luc; Agid, Yves; Vidailhet, Marie; Timmermann, Lars; Deuschl, Günther;
• Is Part Of: Neurology. Volume 92:Number 10(2019)
• Publication Date: 2019-03-05
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000007037
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications. Methods: We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson's Disease Rating Scale (UPDRS) (UPDRS-III "off" and "on" medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI. Results: PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups ( p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group. Conclusion: Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS. Clinicaltrials.gov identifier: NCT00354133.